MDM2 and CDK4 were already familiar as important factors in the pathological diagnosis of liposarcoma, but as MDM2- or CDK4-targeted drugs were investigated, their efficacies against STS (especially liposarcomas) were also evaluated. The gene discussed is MDM2; the disease is liposarcoma.